Glaxo's decision to sell its cancer-drug business to Novartis sent shock waves around the industry—and there could be still more consolidation ahead in the cancer space.
WSJ.com: US Business, Wall Street Journal: Business
Wed, 04/23/2014 - 11:18am
Glaxo's decision to sell its cancer-drug business to Novartis sent shock waves around the industry—and there could be still more consolidation ahead in the cancer space.